<DOC>
	<DOC>NCT01467661</DOC>
	<brief_summary>The purpose of this study is to provide SPD422 to subjects who completed Study SPD422 308 and, in the opinion of the Investigator, will continue to benefit from treatment.</brief_summary>
	<brief_title>Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia, Essential</mesh_term>
	<mesh_term>Anagrelide</mesh_term>
	<criteria>Subjects must have completed Study SPD422 308</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>